Jan Stange from La Jolla, CA

Us Patents

Dosages And Uses Of Ornithine Phenylacetate For Treating Hyperammonemia
view source
US Patent:

20220362192, Nov 17, 2022
Filed:

Oct 15, 2020
Appl. No.:

17/767009
Inventors:

- Hazelwood MO, US
- Bedminster NJ, US
Carmen Mak - Hampton NJ, US
Nagaraju Poola - Belle Mead NJ, US
Regis Vilchez - Chicago IL, US
Aniruddha Potnis - King of Prussia PA, US
Susan VanMeter - Ashburn VA, US
Jan Stange - San Diego CA, US
International Classification:

A61K 31/198
A61P 1/16
Abstract:

Embodiments of the present disclosure relate to doses of ornithine phenylacetate for treating or ameliorating hyperammonemia and the methods of administrating the same in a patient with a chronic liver disease, for example, cirrhosis. In some embodiments, the patient also has hepatic encephalopathy as a complication of the liver disease.

Resumes

Chief Medical Officer

view source

Location:

La Jolla, CA

Industry:

Biotechnology

Work:

Vital Therapies, Inc.
Chief Medical Officer
Janstange
Business Angel Engagements
Octapharma Usa Inc Nov 2012 - Nov 2012
Clinical Advisory Board
Nxstage Medical, Inc. Oct 2012 - Oct 2012
Critical Care Advisory Board
Arbios Systems Jan 2006 - Dec 2007
Chairman of Data Safety Monitoring Board

Education:

Uc San Diego 2000 - 2004
Universität Rostock 1985 - 2000
Doctorates, Masters, Doctor of Philosophy, Doctor of Medicine, Master of Education, Medicine Universität Rostock 1990 - 1991
Master of Education, Masters

Skills:

Life Sciences
Medical Devices
Pharmaceutical Industry
Management
Clinical Trials
Clinical Research
Research
Leadership
Strategic Planning
Biotechnology
Clinical Development
Medicine
Healthcare